Atara advances CAR-T technology with IND clearance Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a next-generation, autologous mesothelin-targeted chimeric antigen receptor T (CAR-T) cell therapy for patients with advanced mesothelioma.
New gene therapy destroys latent oral herpes in mice Researchers recently reported that they were able to eliminate latent herpes simplex virus 1 in mice using a new gene editing technique that targets the root cause of oral herpes. The findings were published on August 18 in Nature Communications. Discuss
Kite submits BLA for CAR-T in non-Hodgkin lymphomas Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory follicular lymphoma or marginal zone lymphomas after two or more prior therapies.